Fig. 2
The association of baseline hematologic indicators with efficacy of ICI plus chemotherapy. Comparisons of baseline hematologic indicators between patients with clinical benefits (CB) and patients with non-benefit (NB) from ICI plus chemotherapy, including absolute lymphocyte count (A), absolute neutrophil count (B), absolute eosinophil count (C), platelet count (D), the ratio of neutrophil-to-lymphocyte (NLR) (E), and the ratio of platelet -to-lymphocyte (PLR)